Regulatory Aspects

Predictive Toxicology: From Vision to Reality

Volumn , Issue , 2015, Pages 369-390

  Lima, Beatriz Silva ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

Author keywords

Biopharmaceuticals; Drug development; Europe; International Conference on Harmonisation (ICH); Monoclonal antibodies (mAbs); United Sates

Indexed keywords

EID: 84926398991     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527674183.ch16     Document Type: Chapter

References (35)

1. FDA (1938) Significant Dates in US Food and Drug Law History, Available at http://www.fda.gov (last accessed February 2014).
2. Rice, E. (2007) Dr. Frances Kelsey: Turning the Thalidomide Tragedy into Food and Drug Administration Reform. Research paper.
3. Greek, R., Shanks, N., and Rice, M.J. (2011) The history and implications of testing thalidomide on animals. J. Philos. Sci. Law, 11, 1-32.
4. Schardein, J.L. (1976) Drugs as Teratogens, CRC Press.
5. Lehman, A.J. et al. (1949) Procedures for the appraisal of the toxicity of chemicals in foods. Food Drug Cosmet. Law Q., 4 (3), 412-434.
6. Jacobs, A.C. and Hatfield, K.P. (2012) History of chronic toxicity and animal carcinogenicity studies for pharmaceuticals. Vet. Pathol., 50 (2), 324-333.
7. Rägo, L. and Santoso, B. (2008) Drug regulation: history, present and future, in Drug Benefits and Risks: International Textbook of Clinical Pharmacology, revised 2nd edn (eds C.J. van Boxtel, B. Santoso, and I.R. Edwards), IOS Press and Uppsala Monitoring Centre.
8. European Commission (1965) Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products. Off. J. L, 22, 369.
9. European Commission (1975) Council Directive 75/318/EEC of 20 May 1975 on the approximation of the laws of Member States relating to analytical, pharmacotoxicological and clinical standards and protocols in respect of the testing of proprietary medicinal products. Off. J. L, 147, 1-12.
10. European Commission (1987) Council Directive 87/22/EEC of 22 December 1986 on the approximation of national measures relating to the placing on the market of high-technology medicinal products, particularly those derived from biotechnology. Off. J. L, 015, 0038-0041.
11. European Commission (1975) Second Council Directive 75/319/EEC of 20 May 1975 on the approximation of provisions laid down by law, regulation or administrative action relating to proprietary medicinal products. Off. J. L, 147, 0013-0022.
12. European Commission (1995) Commission Regulation (EC) No 540/95 of 10 March 1995 laying down the arrangements for reporting suspected unexpected adverse reactions which are not serious, whether arising in the Community or in a third country, to medicinal products for human or veterinary use authorized in accordance with the provisions of Council Regulation (EEC) No 2309/93. Off. J. L, 055, 0005-0006.
13. European Commission (1989) The Rules Governing Medicinal Products in the European Community. Catalogue No. CB-55-89-706-EN-C, Office for Official Publications of the European Communities, Luxembourg.
14. ICH, About ICH: History. Available at www.ich.org (last accessed February 2014).
15. Innovative Medicines Initiative, Ongoing Projects: MARCAR. Available at www.imi. europa.eu (last accessed February 2014).
16. EMA (1995) ICH Guideline M3(R2) on Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorisation for Pharmaceuticals. EMA/CPMP/ICH/286/1995. Available at www.ema.europa.eu (last accessed February 2014).
17. Kola, I. and Landis, J. (2004) A survey of pharmaceutical companies comparing reasons for attrition. Nat. Rev. Drug Discov., 3, 711-715.
18. Arrowsmith, J. and Miller, P. (2013) Phase I and phase II attrition rates 2011-2012. Nat. Rev. Drug Discov., 12, 569.
19. Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., Koen Van Deun, M., Smith, P., Berger, B., and Heller, A. (2000) Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol., 32, 56-67.
20. Innovative Medicines Initiative (2008) The Innovative Medicines Initiative (IMI) Research Agenda. Creating Biomedical R&D Leadership for Europe to Benefit Patients and Society, Version 2.0.
21. Goodsaid, F.M., Frueh, F.W., and Mattes, W. (2007) The Predictive Safety Testing Consortium: a synthesis of the goals, challenges and accomplishments of the critical path. Drug Discov. Today Technol., 4 (2), 47-50.
22. Sistare, F.D., Dieterle, F., Troth, S., Holder, D.J., Gerhold, D., Andrews-Cleavenger, D., Baer, W., Betton, G., Bounous, D., Carl, K., Collins, N., Goering, P., Goodsaid, F., Gu, Y.-Z., Guilpin, V., Harpur, E., Hassan, A., Jacobson-Kram, D., Kasper, P., Laurie, D., Silva-Lima, B., Maciulaitis, R., Mattes, W., Maurer, G., Obert, L.A., Ozer, J., Papaluca-Amati, M., Phillips, J.A., Pinches, M., Schipper, M.J., Thompson, K.L., Vamvakas, S., Vidal, J.M., Vonderscher, J., Walker, E., Webb, C., and Yu, Y. (2010) Towards consensus practices to qualify safety biomarkers for use in early drug development. Nat. Biotechnol., 25, 446-454.
23. Dieterle, F., Sistare, F., Goodsaid, F., Papaluca, M., Ozer, J.S., Webb, C.P., Baer, W., Senagore, A., Schipper, M.J., Vonderscher, J., Sultana, S., Gerhold, D.L., Phillips, J.A., Maurer, G., Carl, K., Laurie, D., Harpur, E., Sonee, M., Ennulat, D., Holder, D., Andrews-Cleavenger, D., Gu, Y.-Z., Thompson, K.L., Goering, P.L., Vidal, J.M., Abadie, E., Maciulaitis, R., Jacobson-Kram, D., Defelice, A.F., Hausner, E.A., Blank, M., Thompson, A., Harlow, P., Throckmorton, D., Xiao, S., Xu, N., Taylor, W., Vamvakas, S., Flamion, B., Lima, B.S., Kasper, P., Pasanen, M., Prasad, K., Troth, S., Bounous, D., Robinson-Gravatt, D., Betton, G., Davis, M.A., Akunda, J., McDuffie, J.E., Suter, L., Obert, L., Guffroy, M., Pinches, M., Jayadev, S., Blomme, E.A., Beushausen, S.A., Barlow, V.G., Collins, N., Waring, J., Honor, D., Snook, S., Lee, J., Rossi, P., Walker, E., and Mattes, W. (2010) Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat. Biotechnol., 28, 455-462.
24. EMA (1998) ICH Guideline S6(R1): Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. EMA/CHMP/ICH/731268/1998. Available at www.ema.europa.eu (last accessed February 2014).
25. van Meer, P.J., Kooijman, M., van der Laan, J.W., Moors, E.H., and Schellekens, H. (2013) The value of non-human primates in the development of monoclonal antibodies. Nat. Biotechnol., 31, 882-883.
26. EMA (2007) Guideline on Strategies to Identify and Mitigate Risks for First-in-Human Clinical Trials with Investigational Medicinal Products. EMEA/CHMP/SWP/28367/07. Available at www.ema.europa. eu (last accessed February 2014).
27. Schneider, C.K., Salmikangas, P., Jilma, B., Flamion, B., Todorova, L.R., Paphitou, A., Haunerova, I., Maimets, T., Trouvin, J.H., Flory, E., Tsiftsoglou, A., Sarkadi, B., Gudmundsson, K., O'Donovan, M., Migliaccio, G., Ancāns, J., Maciulaitis, R., Robert, J.L., Samuel, A., Ovelgönne, J.H., Hystad, M., Fal, A.M., Lima, B.S., Moraru, A.S., Turcáni, P., Zorec, R., Ruiz, S., Akerblom, L., Narayanan, G., Kent, A., Bignami, F., Dickson, J.G., Niederwieser, D., Figuerola-Santos, M.A., Reischl, I.G., Beuneu, C., Georgiev, R., Vassiliou, M., Pychova, A., Clausen, M., Methuen, T., Lucas, S., Schüssler-Lenz, M., Kokkas, V., Buzás, Z., MacAleenan, N., Galli, M.C., Linē, A., Gulbinovic, J., Berchem, G., Fraczek, M., Menezes-Ferreira, M., Vilceanu, N., Hrubisko, M., Marinko, P., Timón, M., Cheng, W., Crosbie, G.A., Meade, N., di Paola, M.L., VandenDriessche, T., Ljungman, P., D'Apote, L., Oliver-Diaz, O., Büttel, I., and Celis, P. (Committee for Advanced Therapies (CAT); CAT Scientific Secretariat) (2010) Challenges with advanced therapy medicinal products and how to meet them. Nat. Rev. Drug Discov., 3, 195-201.
28. EMA (2011) Guideline on the Risk-Based Approach According to Annex I, Part IV of Directive 2001/83/EC Applied to Advanced Therapy Medicinal Products. EMA/CAT/CPWP/686637/2011. Available at www.ema.europa.eu (last accessed February 2014).
29. EMA (2010) European Medicines Agency Guidance for Companies Requesting Scientific Advice and Protocol Assistance. EMEA-H-4260-01 Rev. 6. Available at www.ema.europa.eu (last accessed February 2014).
30. McNeil (2009) Nanoparticle therapeutics: a personal perspective. Nanomed. Nanobiotechnol., 1, 264-271.
31. Ehmann, F., Sakai-Kato, K., Duncan, R., Hernán Pérez de la Ossa, D., Pita, R., Vidal, J.M., Kohli, A., Tothfalusi, L., Sanh, A., Tinton, S., Robert, J.L., Silva Lima, B., and Amati, M.P. (2013) Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines. Nanomedicine, 8 (5), 849-856.
32. EMA (2005) Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies: Non-Clinical and Clinical Issues. EMA/CHMP/BMWP/403543/2010. Available at www.ema. europa.eu (last accessed February 2014).
33. Manolis, E., Rohou, S., Hemmings, R., Salmonson, T., Karlsson, M., and Milligan, P.A. (2013) The role of modeling and simulation in development and registration of medicinal products: output from the EFPIA/EMA Modeling and Simulation Workshop. CPT Pharmacometrics Syst. Pharmacol., 2, e31.
34. Colins, F.S. (2011) Reengineering translational science: the time is right. Sci. Transl. Med., 3 (90), 90cm17.
35. EMA (2011) Concept Paper on the Need for Revision of the Position on the Replacement of Animal Studies by In Vitro Models. EMA/CHMP/SWP/169839/2011. Available at www.ema.europa.eu (last accessed February 2014).